Drug-resistant tuberculosis: World Health Organization launches Global Response Plan 2007-2008

2007 ◽  
Vol 12 (27) ◽  
Author(s):  
Collective Editorial team
Keyword(s):  
World Health ◽  
Drug Resistant ◽  
First Line ◽  
Global Response ◽  
Drug Resistant Tuberculosis ◽  
Resistant Tuberculosis ◽  
Resistant Strains ◽  
Response Plan ◽  
Health Organization ◽  
Drug Resistant Strains

An increasing proportion of tuberculosis (TB) cases today are resistant to first line, and often also to second line anti-TB drugs. Drug-resistant strains of Mycobacterium tuberculosis are now responsible for over 400,000 cases of TB per year.

scholarly journals Tuberculosis drug resistance in Canada, 1998 to 2000

2001 ◽  
Vol 12 (3) ◽  
pp. 141-143
Author(s):  
Melissa D Phypers ◽  
Linda Panaro ◽  
Penny Nault
Keyword(s):  
World Health ◽  
Drug Resistant ◽  
First Line ◽  
International Union ◽  
The World ◽  
Resistant Strains ◽  
Health Organization ◽  
Global Threat ◽  
Drug Resistant Strains ◽  
And Control

The emergence of drug-resistant strains of tuberculosis (TB) is a global threat to TB prevention and control efforts. A recent study conducted by the World Health Organization (WHO) and the International Union Against Tuberculosis and Lung Disease found strains of TB resistant to first-line anti-TB drugs in all countries surveyed (1). The WHO estimates that 50 million people are infected with strains of drug-resistant TB (2).

Management of Multidrug-Resistant Tuberculosis

2018 ◽  
Vol 39 (03) ◽  
pp. 310-324 ◽  
Author(s):  
Jose Caminero ◽  
Charles Daley
Keyword(s):  
Multidrug Resistant ◽  
New Drugs ◽  
World Health ◽  
Drug Resistant ◽  
Resistant Tuberculosis ◽  
Multidrug Resistant Tuberculosis ◽  
Mdr Tb ◽  
Resistant Strains ◽  
Health Organization ◽  
Drug Resistant Strains

AbstractDrug-resistant strains of Mycobacterium tuberculosis pose a major threat to global tuberculosis control. Despite the availability of curative antituberculosis therapy for nearly half a century, inappropriate and inadequate treatment of tuberculosis, as well as unchecked transmission of M. tuberculosis, has resulted in alarming levels of drug-resistant tuberculosis. The World Health Organization (WHO) estimates that there were 600,000 cases of multidrug-resistant tuberculosis (MDR-TB)/rifampin-resistant (RR) tuberculosis in 2016, defined as strains that are resistant to at least isoniazid and rifampicin. Globally, WHO estimates that 4.1% of new tuberculosis cases and 19% of retreatment cases have MDR-TB. By the end of 2016, 123 countries had reported at least one case of extensively drug-resistant strains, which are MDR-TB strains that have acquired additional resistance to fluoroquinolones and at least one second-line injectable. It is estimated that only 22% of all MDR-TB cases are currently receiving therapy. This article reviews the management of MDR/RR-TB and updates recommendations regarding the use of shorter course regimens and new drugs.

scholarly journals Prevalence of primary drug resistant tuberculosis in a tertiary care hospital, Nepal

2015 ◽  
Vol 4 (4) ◽  
pp. 36-38
Author(s):  
R Khunjeli ◽  
U R Mohsin ◽  
S K Shrestha ◽  
S Adhikari ◽  
B Srivastava ◽  
...  
Keyword(s):  
Armed Forces ◽  
Care Hospital ◽  
Drug Resistant ◽  
Newly Diagnosed ◽  
First Line ◽  
Sensitivity Testing ◽  
Drug Resistant Tuberculosis ◽  
Resistant Tuberculosis ◽  
Resistant Strains ◽  
Primary Drug

 Background & objectives: Tuberculosis is a transmissible disease mainly due to inhalation of infected droplet nuclei. The burden of drug resistant tuberculosis is very high in our neighboring countries India and China. Prevalence of primary drug resistant disease is difficult to estimate in our country because culture and sensitivity is not done routinely. This study was an attempt to find out the prevalence of drug resistant in newly diagnosed tuberculosis patients serving in the Nepalese Armed Forces. Methodology: Medical records of patients serving in the Nepalese Armed Forces who had the provisional diagnosis of pulmonary tuberculosis for the first time from July 2012 to June 2014 were analyzed. They had their sputum subjected for both smear and culture with sensitivity testing. Out of 134 patients, 62 had culture positive for Mycobacterium tuberculosis and drug sensitivity was done for the first line 4 antitubercular drugs. Results: Drug resistant strains were found in 5 cases (8.1%) of which 2 (3.2%) were resistant to 4 first line drugs - rifampicin, isoniazid, ethambutol and streptomycin. Prevalence of isoniazid resistance was the highest, found in 3 cases (4.8%). Conclusion: Primary drug resistant tuberculosis in newly diagnosed cases was high even in young healthy adults, and isoniazid resistant strains were the commonest.DOI: http://dx.doi.org/10.3126/jcmc.v4i4.11970

scholarly journals Directrices unificadas de la OMS sobre el tratamiento de la tuberculosis farmacorresistente

2020 ◽  
Keyword(s):  
World Health Organization ◽  
Tuberculosis Treatment ◽  
World Health ◽  
Drug Resistant ◽  
Drug Resistant Tuberculosis ◽  
Resistant Tuberculosis ◽  
Health Organization

Estas directrices unificadas se han actualizado con arreglo a los procesos del grupo de elaboración de las directrices que se llevaron a cabo entre el 2011 y el 2018 de conformidad con los requisitos de la OMS. Este documento sustituye a otras recomendaciones de la OMS relativas al tratamiento de la tuberculosis (TB) multirresistente y resistente a la rifampicina (TB-MDR/RR) publicadas desde el 201. En este documento se incluyen las preguntas sobre población, intervención, comparador y resultado (PICO, por su sigla en inglés) subyacentes a las recomendaciones y la posología revisada de los medicamentos utilizados en los esquemas de segunda línea, así como las referencias clave. En línea se puede encontrar más información sobre los procesos del grupo de elaboración de las directrices y los participantes en dicho grupo, los principales métodos utilizados para desarrollar las recomendaciones, los resúmenes de la evidencia de la clasificación de la valoración, elaboración y evaluación de las recomendaciones (GRADE por su sigla en inglés) resultante y los marcos de decisión para cada recomendación, así como datos inéditos, planes de análisis de datos e informes de revisiones sistemáticas. Las recomendaciones y demás información práctica para apoyar su implementación se reproducirán en una próxima actualización del manual de la OMS sobre el manejo programático de la TB. Versión oficial en español de la obra original en inglés: WHO consolidated guidelines on drug-resistant tuberculosis treatment. © World Health Organization 2019. ISBN: 978-92-4-155052-9.

scholarly journals The future of drug-resistant tuberculosis treatment: learning from the past and the 2019 World Health Organization consolidated guidelines

2019 ◽  
Vol 54 (4) ◽  
pp. 1901272 ◽  
Author(s):  
José A. Caminero ◽  
Alberto L. García-Basteiro ◽  
Adrián Rendon ◽  
Alberto Piubello ◽  
Emanuele Pontali ◽  
...  
Keyword(s):  
World Health Organization ◽  
Tuberculosis Treatment ◽  
World Health ◽  
Drug Resistant ◽  
Drug Resistant Tuberculosis ◽  
The Past ◽  
Resistant Tuberculosis ◽  
The Future ◽  
Health Organization

scholarly journals Pharmacokinetics of Levofloxacin in Children Treated for Exposure to Drug-Resistant Tuberculosis

2019 ◽  
Vol 63 (5) ◽  
Author(s):  
Amyn A. Malik ◽  
Meredith B. Brooks ◽  
Sara Siddiqui ◽  
Junaid Fuad ◽  
Charles A. Peloquin ◽  
...  
Keyword(s):  
Drug Exposure ◽  
Preventive Therapy ◽  
World Health ◽  
Serum Drug Concentration ◽  
Drug Resistant ◽  
Drug Resistant Tuberculosis ◽  
Resistant Tuberculosis ◽  
Drug Concentrations ◽  
Exposure Target ◽  
Health Organization

ABSTRACT Levofloxacin is used to treat and prevent drug-resistant tuberculosis in children. We assessed levofloxacin serum drug concentrations in 24 children aged 2 to 10 years who received levofloxacin-based tuberculosis preventive therapy in Karachi, Pakistan. Only 9 children (37.5%) achieved adequate drug exposure. Target serum drug concentration was met in 4 (26.7%) of 15 children dosed consistently with World Health Organization recommendations and 4 (80.0%) of 5 who received higher-than-recommended doses. Levofloxacin dosing recommendations may require reevaluation.

scholarly journals Safety of treatment regimens in multiple drug resistant tuberculosis patients compiled as per the new WHO recommendations as of 2019

2020 ◽  
Vol 98 (1) ◽  
pp. 5-15
Author(s):  
D. A. Ivanova ◽  
S. E. Borisov ◽  
O. V. Rodina ◽  
A. V. Filippov ◽  
T. N. Ivanushkina ◽  
...  
Keyword(s):  
Risk Factors ◽  
World Health ◽  
Multiple Drug ◽  
Drug Resistant ◽  
Drug Resistant Tuberculosis ◽  
Treatment Regimens ◽  
Resistant Tuberculosis ◽  
Multiple Drug Resistant ◽  
Group A ◽  
Health Organization

The objective: safety assessment of chemotherapy regimens compiled in accordance with the recommendations of World Health Organization (WHO), 2019, in patients with multiple drug resistant tuberculosis (MDR) in clinical practice settings.Subjects: Frequency, patterns, severity and risk factors of adverse events (AE) of chemotherapy regimens compiled in accordance with the WHO recommendations as of 2019 were analyzed in 122 patients with MDR and XDR respiratory tuberculosis within programmatic use of new anti-tuberculosis drugs.Results. The frequency of AE made 64.8% (95% CI 55.9-72.7%), gastrointestinal, cardiovascular and allergic events prevailed, the comorbidity was the risk factor of AE development (OR 6.44; 95% CI 1.91-21.76). AEs of with severity degrees 3-4 were observed in 24.6% (95% CI 17.8-33.0%), neurotoxic, ototoxic and hepatotoxic reactions prevailed; risk factors included female sex (OR 3.15, 95% CI 1.32-7.53) and complications of chemotherapy in the past (OR 3.50%, 95% CI 1.49-8.70). At least one anti-tuberculosis drug was canceled due to AE in 26.2% (95% CI 19.2-34.7%), and any of Group A drugs was canceled during the first 6 months of chemotherapy in 13.9% (95% CI 8.8-21.3%) of patients.

Sign in / Sign up

Export Citation Format

Share Document